EUCTR2017-004065-27-GB进行中（未招募）1 期
Open Label Extension Study For Continued Safety And Efficacy Evaluation Of Azeliragon In Patients With Mild Alzheimer's Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Successful completion of Study TTP488-301 through the Month 18 Visit without ongoing SAEs or history of serious adverse drug reactions during study TTP488-301.
- •2. Patients must enroll in the present study within 7 days of completion of study TTP488-301.
- •3. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally authorized representative) and caregiver/informant has been informed of all pertinent aspects of the study. Participants must be able to provide assent (where this is in accordance with local laws, regulations and ethics committee policy) and assent may be re-evaluated during the study at regular intervals.
- •4. Participants and caregiver/informants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •5. The subject must have a reliable caregiver/informant with regular contact (i.e., 10 hours a week as a combination of face-to-face visits and telephone contacts are acceptable) who will facilitate the subject’s full participation in the study. Caregivers/informant must have sufficient subject interaction to be able to provide meaningful input into the rating scales administered in this study where caregiver/informant input is required, in particular the CDR and evidence of this should be documented in source documentation. Participants who reside in assisted living facilities are permitted provided that they meet caregiver/informant criteria.
- •6. Participants and caregiver/informants must be able to read, write, and speak the language in which psychometric tests are provided with visual and auditory acuity (corrected) sufficient to allow for accurate psychometric testing.
- •7. Subject must be able to ingest oral medications.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 110
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 690
排除标准
- •Participants presenting with any of the following will be excluded from participation in the study.
- •1. The subject is felt by the investigator to be unsuitable (on the basis of health, compliance, caregiver availability, or for any other reason) for inclusion in the study.
- •2. Subjects with serious suicide risk. If there are yes” answers on items 4, 5 or on any behavioral question of the C-SSRS, a suicide risk assessment must be done by a qualified mental health professional with expertise in the evaluation of suicidality in the elderly (e.g., psychiatrist, geriatrician or neurologist specializing in treatment of patients with AD) to determine whether it is safe for the subject to participate in the study.
- •3. Subjects demonstrating a QTcF > 480 msec or a >45 msec increase from the TTP488-301 Baseline value based on the locally read ECG performed at the TTP488-301 Month 18 Visit (TTP488-303 Baseline). Participants with known history of bundle branch block (either right or left) are allowed if absolute QTcF value does not exceed 500 msec. Participants with a functioning pacemaker, indicated by an ECG displaying paced rhythm, are allowed with no QTc upper limit.
- •4. Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may prevent the subject from completing the 2-year study or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial.
研究者
相似试验
已完成
2 期
A Phase II Extension study to assess the safety and tolerability of PBT2 and its effect on amyloid levels in the brains of patients with prodromal or mild Alzheimer's disease.ACTRN12613000777796Alterity Therapeutics33
进行中（未招募）
不适用
uncontrolled epilepsyEUCTR2009-017904-95-DEpsher-Smith Laboratories, Inc.275
进行中（未招募）
不适用
Open-Label Extension Study to Evaluate the Safety of USL255 as Adjunctive Therapy in Patients with Refractory Partial-Onset Seizures who had Participated in P09-004, a Randomized, Multicenter, Double-Blind, Placebo–Controlled, Parallel-Group, Phase 3 StudyRefractory partial-onset seizures with or without secondary generalizationMedDRA version: 14.0Level: PTClassification code 10056209Term: Partial seizures with secondary generalisationSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: PTClassification code 10040703Term: Simple partial seizuresSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: LLTClassification code 10034090Term: Partial seizures, complexSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: LLTClassification code 10048674Term: Partial seizures with secondary generalizationSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: PTClassification code 10010145Term: Complex partial seizuresSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: LLTClassification code 10034091Term: Partial seizures, simpleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-017904-95-GRpsher-Smith Laboratories, Inc.172
进行中（未招募）
不适用
Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset SeizuresRefractory partial-onset seizures with or without secondary generalizationMedDRA version: 14.0Level: PTClassification code 10056209Term: Partial seizures with secondary generalisationSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: PTClassification code 10040703Term: Simple partial seizuresSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: LLTClassification code 10034090Term: Partial seizures, complexSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: LLTClassification code 10048674Term: Partial seizures with secondary generalizationSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: PTClassification code 10010145Term: Complex partial seizuresSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: LLTClassification code 10034091Term: Partial seizures, simpleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-017904-95-HUpsher-Smith Laboratories, Inc.172
进行中（未招募）
1 期
Clinical Trial Extension Study with Avapritinib for Patients with Gastrointestinal Stromal Tumorsocally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)MedDRA version: 21.1Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-005751-21-FRBlueprint Medicines5